115 related articles for article (PubMed ID: 38749067)
21. T-cell depletion plus salvage immunotherapy with donor leukocyte infusions as a strategy to treat chronic-phase chronic myelogenous leukemia patients undergoing HLA-identical sibling marrow transplantation.
Drobyski WR; Hessner MJ; Klein JP; Kabler-Babbitt C; Vesole DH; Margolis DA; Keever-Taylor CA
Blood; 1999 Jul; 94(2):434-41. PubMed ID: 10397710
[TBL] [Abstract][Full Text] [Related]
22. Phase 1/2 study of nilotinib prophylaxis after allogeneic stem cell transplantation in patients with advanced chronic myeloid leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemia.
Shimoni A; Volchek Y; Koren-Michowitz M; Varda-Bloom N; Somech R; Shem-Tov N; Yerushalmi R; Nagler A
Cancer; 2015 Mar; 121(6):863-71. PubMed ID: 25387866
[TBL] [Abstract][Full Text] [Related]
23. Pretransplantation use of the second-generation tyrosine kinase inhibitors has no negative impact on the HCT outcome.
Piekarska A; Gil L; Prejzner W; Wiśniewski P; Leszczyńska A; Gniot M; Komarnicki M; Hellmann A
Ann Hematol; 2015 Nov; 94(11):1891-7. PubMed ID: 26220759
[TBL] [Abstract][Full Text] [Related]
24. [Effects and prognostic factors of HLA-matched sibling donor allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia].
Tong XZ; Li J; Tan EX; Zhang GC; Wu XY; Peng AH; Zheng D; Zou WY; Hong WD; Luo SK
Zhonghua Zhong Liu Za Zhi; 2006 Jul; 28(7):545-8. PubMed ID: 17147125
[TBL] [Abstract][Full Text] [Related]
25. [Impact of HLA compatibility on the outcome of allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia].
ZHANG Y; CHEN YK; FAN ZP; XU D; JIANG QL; SUN J; LIU QF
Nan Fang Yi Ke Da Xue Xue Bao; 2011 Mar; 31(3):438-42. PubMed ID: 21421478
[TBL] [Abstract][Full Text] [Related]
26. Outcome of Chinese patients with chronic myeloid leukaemia (CML) underwent allogeneic bone-marrow transplantation (BMT).
Lee CK; Lie AK; Liang R; Au WY; Chen FE; Chim CS; Kwong YL
Am J Hematol; 1999 Jun; 61(2):85-9. PubMed ID: 10367784
[TBL] [Abstract][Full Text] [Related]
27. Transplant to treatment-free remission: the evolving view of 'cure' in chronic myeloid leukemia.
Yong AS; Brissot E; Rubinstein S; Savani BN; Mohty M
Expert Rev Hematol; 2015 Dec; 8(6):785-97. PubMed ID: 26364871
[TBL] [Abstract][Full Text] [Related]
28. Patients with Philadelphia-positive leukemia with BCR-ABL kinase mutations before allogeneic transplantation predominantly relapse with the same mutation.
Egan DN; Beppu L; Radich JP
Biol Blood Marrow Transplant; 2015 Jan; 21(1):184-9. PubMed ID: 25300870
[TBL] [Abstract][Full Text] [Related]
29. Effect of graft sources on allogeneic hematopoietic stem cell transplantation outcome in adults with chronic myeloid leukemia in the era of tyrosine kinase inhibitors: a Japanese Society of Hematopoietic Cell Transplantation retrospective analysis.
Ohashi K; Nagamura-Inoue T; Nagamura F; Tojo A; Miyamura K; Mori T; Kurokawa M; Taniguchi S; Ishikawa J; Morishima Y; Atsuta Y; Sakamaki H
Int J Hematol; 2014 Sep; 100(3):296-306. PubMed ID: 25085253
[TBL] [Abstract][Full Text] [Related]
30. Outcome of allogeneic SCT in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy.
Oyekunle A; Zander AR; Binder M; Ayuk F; Zabelina T; Christopeit M; Stübig T; Alchalby H; Schafhausen P; Lellek H; Wolschke C; Müller I; Bacher U; Kröger N
Ann Hematol; 2013 Apr; 92(4):487-96. PubMed ID: 23250623
[TBL] [Abstract][Full Text] [Related]
31. Prognostic factors for outcomes in allogeneic transplantation for CML in the imatinib era: a CIBMTR analysis.
Khoury HJ; Kukreja M; Goldman JM; Wang T; Halter J; Arora M; Gupta V; Rizzieri DA; George B; Keating A; Gale RP; Marks DI; McCarthy PL; Woolfrey A; Szer J; Giralt SA; Maziarz RT; Cortes J; Horowitz MM; Lee SJ
Bone Marrow Transplant; 2012 Jun; 47(6):810-6. PubMed ID: 21986636
[TBL] [Abstract][Full Text] [Related]
32. Challenges for allogeneic hematopoietic stem cell transplantation in chronic myeloid leukemia in the era of tyrosine kinase inhibitors.
Oyekunle A; Klyuchnikov E; Ocheni S; Kröger N; Zander AR; Baccarani M; Bacher U
Acta Haematol; 2011; 126(1):30-9. PubMed ID: 21411987
[TBL] [Abstract][Full Text] [Related]
33. The risk of residual molecular and cytogenetic disease in patients with Philadelphia-chromosome positive first chronic phase chronic myelogenous leukemia is reduced after transplantation of allogeneic peripheral blood stem cells compared with bone marrow.
Elmaagacli AH; Beelen DW; Opalka B; Seeber S; Schaefer UW
Blood; 1999 Jul; 94(2):384-9. PubMed ID: 10397704
[TBL] [Abstract][Full Text] [Related]
34. Role of pretransplant interferon-alpha(IFN) treatment in the outcome of stem cell transplantation (SCT) from related donors in chronic myelogenous leukemia (CML): results from three Turkish transplant centers.
Beksac M; Celebi H; Sargín D; Yalcin A; Topcuoglu P; Kalayoglu-Besisik S; Beyan C; Arslan O; Ozcan M; Gurman G; Ilhan O; Akan H
Bone Marrow Transplant; 2003 May; 31(10):897-904. PubMed ID: 12748666
[TBL] [Abstract][Full Text] [Related]
35. Maintenance Tyrosine Kinase Inhibitors Following Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Myelogenous Leukemia: A Center for International Blood and Marrow Transplant Research Study.
DeFilipp Z; Ancheta R; Liu Y; Hu ZH; Gale RP; Snyder D; Schouten HC; Kalaycio M; Hildebrandt GC; Ustun C; Daly A; Ganguly S; Inamoto Y; Litzow M; Szer J; Savoie ML; Hossain N; Kharfan-Dabaja MA; Hamadani M; Reshef R; Bajel A; Schultz KR; Gadalla S; Gerds A; Liesveld J; Juckett MB; Kamble R; Hashmi S; Abdel-Azim H; Solh M; Bacher U; Lazarus H; Olsson R; Cahn JY; Grunwald MR; Savani BN; Yared J; Rowe JM; Cerny J; Chaudhri NA; Aljurf M; Beitinjaneh A; Seo S; Nishihori T; Hsu JW; Ramanathan M; Alyea E; Popat U; Sobecks R; Saber W
Biol Blood Marrow Transplant; 2020 Mar; 26(3):472-479. PubMed ID: 31669399
[TBL] [Abstract][Full Text] [Related]
36. Extended follow-up of patients treated with imatinib mesylate (gleevec) for chronic myelogenous leukemia relapse after allogeneic transplantation: durable cytogenetic remission and conversion to complete donor chimerism without graft-versus-host disease.
DeAngelo DJ; Hochberg EP; Alyea EP; Longtine J; Lee S; Galinsky I; Parekkedon B; Ritz J; Antin JH; Stone RM; Soiffer RJ
Clin Cancer Res; 2004 Aug; 10(15):5065-71. PubMed ID: 15297408
[TBL] [Abstract][Full Text] [Related]
37. Treosulfan and fludarabine low-toxicity conditioning for allogeneic haematopoietic stem cell transplantation in chronic myeloid leukaemia.
Holowiecki J; Giebel S; Wojnar J; Krawczyk-Kulis M; Markiewicz M; Holowiecka-Goral A; Freund M; Casper J
Br J Haematol; 2008 Jun; 142(2):284-92. PubMed ID: 18492101
[TBL] [Abstract][Full Text] [Related]
38. Does Post-Transplant Maintenance Therapy With Tyrosine Kinase Inhibitors Improve Outcomes of Patients With High-Risk Philadelphia Chromosome-Positive Leukemia?
DeFilipp Z; Langston AA; Chen Z; Zhang C; Arellano ML; El Rassi F; Flowers CR; Kota VK; Al-Kadhimi Z; Veldman R; Jillella AP; Lonial S; Waller EK; Khoury HJ
Clin Lymphoma Myeloma Leuk; 2016 Aug; 16(8):466-471.e1. PubMed ID: 27297665
[TBL] [Abstract][Full Text] [Related]
39. Allogeneic stem cell transplant for chronic myeloid leukemia as a still promising option in the era of the new target therapy.
Stamatović D; Balint B; Tukić L; Elez M; Tarabar O; Todorović M; Todorić-Zivanović B; Ostojić G; Tatomirović Z; Marjanović S; Malesević M
Vojnosanit Pregl; 2012 Jan; 69(1):37-42. PubMed ID: 22397295
[TBL] [Abstract][Full Text] [Related]
40. [HLA-identical sibling allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia in first chronic phase. Analysis of 51 cases].
He Y; Feng SZ; Wang M; Wei JL; Qin TJ; Zhou Z; Zhai WJ; Qiu LG; Han MZ
Zhonghua Xue Ye Xue Za Zhi; 2005 Jul; 26(7):389-92. PubMed ID: 16251016
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
